Zhitong Finance App News, Changfeng Pharmaceutical (02652.HK) announced that the Phase I clinical trial of ICF004 (Chemical Drug Class 1) (ICF004) for the treatment of interstitial lung disease (ILD) developed by the Group has completed the enrollment and administration of the first healthy subject. These developments indicate that ICF004 has entered the patient administration phase after being approved to conduct this phase I clinical trial.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.